Cagrilintide
Cagrilintide (AM833, NNC0174-0833)
Long-acting synthetic amylin analogue for weight management and type 2 diabetes. Works as a dual amylin and calcitonin receptor agonist (DACRA), mimicking natural amylin hormone to regulate appetite, slow gastric emptying, and promote satiety.
Complete Dosing Guide
What is Cagrilintide?
Cagrilintide (also known as AM833 or NNC0174-0833) is a long-acting synthetic amylin analogue being investigated for weight management and type 2 diabetes. It works as a dual amylin and calcitonin receptor agonist (DACRA), mimicking the natural hormone amylin that helps regulate appetite, slows gastric emptying, and promotes satiety.
When is Cagrilintide Used?
Weight Management:
- For adults with obesity (BMI ≥30 kg/m²)
- For overweight adults (BMI ≥27 kg/m²) with weight-related conditions
- Often combined with semaglutide (CagriSema) for enhanced weight loss
Type 2 Diabetes:
- To improve glycemic control alongside metformin
- To support weight loss in diabetic patients
- May help with insulin resistance
What is Cagrilintide?
Cagrilintide (also known as AM833 or NNC0174-0833) is a long-acting synthetic amylin analogue being investigated for weight management and type 2 diabetes. It works as a dual amylin and calcitonin receptor agonist (DACRA), mimicking the natural hormone amylin that helps regulate appetite, slows gastric emptying, and promotes satiety.
When is Cagrilintide Used?
Weight Management:
- For adults with obesity (BMI ≥30 kg/m²)
- For overweight adults (BMI ≥27 kg/m²) with weight-related conditions
- Often combined with semaglutide (CagriSema) for enhanced weight loss
Type 2 Diabetes:
- To improve glycemic control alongside metformin
- To support weight loss in diabetic patients
- May help with insulin resistance
Medical Disclaimer
Clinical data presented is from peer-reviewed studies. Individual results may vary. Consult healthcare professionals before starting treatment. This information is for educational purposes only.